ModernaA Phase III win for Moderna and Merck’s personalized mRNA cancer vaccine has reignited investor enthusiasm for mRNA — and put BioNTech back in the spotlight. But the data are more important than the stock rally: for the first time, a personalized mRNA cancer therapy has produced positive Phase III data in a major indication.
Tag Archive for: RNA
BioSpringBioSpring GmbH has broken found for one of the world’s largest production facilities for pharmaceutical nucleic acid-based therapeutics. The new high-tech plant will significantly expand the company’s manufacturing capacity for RNA- and DNA-based active pharmaceutical ingredients, and will support Good Manufacturing Practice (GMP)-compliant production for large-scale projects on behalf of BioSpring’s global partners.
adobe stock - Monty Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI) has granted US$5m to RNA formulation specialis Ethris to support studies that demonstrate spray-dried RNA vaccines remain stable at room temperature and are suitable for mucosal delivery.
Image by Pete Linforth from Pixabay.Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.
A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.